Daniel M Altmann Selected Research

Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)

9/2007	Sexual dimorphism in superantigen shock involves elevated TNF-alpha and TNF-alpha induced hepatic apoptosis.
11/2005	The mechanism of superantigen-mediated toxic shock: not a simple Th1 cytokine storm.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel M Altmann Research Topics

Disease

33	Infections 10/2023 - 09/2002
23	COVID-19 02/2024 - 12/2020
9	Multiple Sclerosis 06/2015 - 07/2004
8	Anthrax 09/2022 - 04/2010
7	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 11/2023 - 12/2012
5	Neoplasms (Cancer) 01/2021 - 10/2018
5	Melioidosis 01/2018 - 01/2011
5	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 06/2009 - 08/2004
4	Breakthrough Infections 10/2023 - 01/2022
4	Cutaneous anthrax 09/2022 - 04/2010
4	Rheumatoid Arthritis 01/2022 - 01/2006
3	Virus Diseases (Viral Diseases) 01/2022 - 01/2017
3	Arthritis (Polyarthritis) 01/2022 - 02/2006
3	Sepsis (Septicemia) 01/2019 - 09/2007
3	Inflammation (Inflammations) 01/2019 - 12/2012
3	Bacterial Infections (Bacterial Infection) 11/2018 - 04/2010
3	Bronchiectasis 11/2018 - 02/2006
3	Disease Susceptibility (Diathesis) 06/2015 - 09/2009
3	Septic Shock (Toxic Shock Syndrome) 09/2007 - 02/2004
2	Elephantiasis 03/2024 - 12/2020
2	Human Influenza (Influenza) 11/2023 - 01/2012
2	Reinfection 01/2023 - 01/2021
2	Cystic Fibrosis (Mucoviscidosis) 12/2014 - 01/2011
2	Prion Diseases (Transmissible Spongiform Encephalopathies) 11/2008 - 11/2006
2	Shock 09/2007 - 11/2005
2	Paralysis (Palsy) 02/2005 - 07/2004
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2023
1	Atherosclerosis 11/2022
1	Atopic Dermatitis (Atopic Eczema) 01/2022
1	Severe Acute Respiratory Syndrome 01/2022
1	Disease Progression 01/2022

Drug/Important Bio-Agent (IBA)

27	VaccinesIBA 02/2024 - 11/2006
17	EpitopesIBA 09/2022 - 07/2004
14	AntigensIBA 11/2022 - 01/2006
13	Proteins (Proteins, Gene)FDA Link 11/2022 - 08/2004
8	COVID-19 VaccinesIBA 11/2023 - 01/2022
8	CytokinesIBA 01/2022 - 09/2005
7	Peptides (Polypeptides)IBA 05/2015 - 07/2004
6	T-Cell Antigen Receptors (T-Cell Receptor)IBA 03/2024 - 07/2004
6	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 11/2018 - 07/2009
4	Infliximab (Remicade)FDA Link 11/2023 - 01/2022
4	AntibodiesIBA 10/2023 - 05/2014
4	HLA-DR1 Antigen (HLA DR1 Antigen)IBA 04/2014 - 11/2005
3	Neutralizing AntibodiesIBA 02/2024 - 12/2020
3	tofacitinibIBA 11/2023 - 01/2022
3	(N- Ac- His(1)- Nle(17)- Arg(20,21)- Ala(26))- vasoactive intestinal peptideIBA 10/2023 - 01/2022
3	Combined VaccinesIBA 10/2023 - 05/2010
3	vedolizumabIBA 01/2023 - 01/2022
3	Anthrax Vaccines (Vaccines, Anthrax)IBA 09/2022 - 04/2010
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 07/2009
3	Anti-Bacterial Agents (Antibiotics)IBA 12/2020 - 04/2010
3	HLA Antigens (Human Leukocyte Antigens)IBA 01/2019 - 06/2015
3	KIR ReceptorsIBA 01/2019 - 02/2006
3	HLA-DR15 antigenIBA 06/2015 - 02/2005
3	Immunodominant EpitopesIBA 06/2015 - 11/2006
3	Myelin Basic ProteinIBA 02/2012 - 08/2004
3	SuperantigensIBA 09/2007 - 02/2004
2	Immunoglobulins (Immunoglobulin)IBA 03/2024 - 01/2022
2	RNA (Ribonucleic Acid)IBA 03/2024 - 10/2021
2	HLA-DR Antigens (HLA-DR)IBA 03/2024 - 01/2022
2	Methotrexate (Mexate)FDA LinkGeneric 02/2024 - 01/2022
2	mRNA VaccinesIBA 10/2023 - 04/2021
2	Influenza Vaccines (Influenza Vaccine)FDA Link 06/2023 - 01/2022
2	Messenger RNA (mRNA)IBA 01/2023 - 01/2022
2	IntegrinsIBA 01/2023 - 01/2022
2	NucleoproteinsIBA 01/2023 - 01/2022
2	anthrax toxin (anthrax lethal factor)IBA 09/2022 - 01/2015
2	BNT162 VaccineIBA 01/2022 - 04/2021
2	InterferonsIBA 01/2022 - 01/2021
2	HLA-DRB1 Chains (HLA DRB1)IBA 01/2022 - 06/2015
2	ClaudinsIBA 11/2018 - 06/2015
2	AutoantigensIBA 05/2015 - 02/2006
2	Heroin (Diamorphine)IBA 03/2015 - 02/2014
2	AllergensIBA 04/2014 - 07/2009
2	Interleukin-17 (Interleukin 17)IBA 07/2012 - 06/2009
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2007 - 11/2005
2	Collagen Type II (Type II Collagen)IBA 05/2007 - 02/2006
1	Scavenger Receptors (Scavenger Receptor)IBA 03/2024
1	Histones (Histone)IBA 03/2024
1	ClayIBA 03/2024
1	SARS-CoV-2 spike proteinIBA 02/2024
1	2-mercaptopurineIBA 11/2023
1	Glycoproteins (Glycoprotein)IBA 10/2023
1	Janus Kinase InhibitorsIBA 10/2023
1	Blocking AntibodiesIBA 01/2023
1	N-(2-cyanoethylene)urea (BA 1)IBA 01/2023
1	Tyrosine Kinase InhibitorsIBA 01/2023
1	CholesterolIBA 11/2022
1	ProteomeIBA 11/2022
1	Complement System Proteins (Complement)IBA 11/2022
1	LipidsIBA 11/2022
1	edema factorIBA 09/2022
1	ExotoxinsIBA 09/2022
1	Growth Differentiation Factor 15IBA 01/2022
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022
1	Vascular Endothelial Growth Factor CIBA 01/2022
1	ChemokinesIBA 01/2022

Therapy/Procedure

7	Therapeutics 11/2023 - 07/2004
5	Immunotherapy 01/2021 - 01/2006
2	Biological Therapy 01/2023 - 01/2023